# Universal Health Services, Inc. (UHS)

> Source: Nexqual · https://nexqual.com/UHS · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Universal Health Services, Inc. (UHS), nexqual.com/UHS" · informational, not investment advice.

**Price:** USD 188.13 (+2.88% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 182.87 · day 182.94–188.86 · 52w 140.08–246.33 · market cap $11.1B · NYQ

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $18.1B, net income $1.53B (8.4% margin), free cash flow $845M (SEC filings).
- Valuation: P/E 7.3x (avg 11.7x at the last 3 fiscal year-ends), EV/EBITDA 5.9x, net debt $4.76B.
- 2 of 80 tracked superinvestors hold UHS (13F, Q2 2026): 0 new, 2 added, 0 reduced, 0 unchanged.
- Analysts: Hold (mean 2.80 on a 1–5 scale) (20 analysts), mean target USD 196.12 (range 166–290).
- Total return with dividends: 1Y -9.4% vs S&P 500 +14.9%; 5Y +42.3% vs S&P 500 +80.3%.
- Next earnings: 2026-10-27, EPS estimate USD 5.15, revenue estimate $4.71B.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $12.6B | $13.4B | $14.3B | $15.8B | $17.4B | $18.1B |
| Operating income | $1.36B | $1.00B | $1.18B | $1.68B | $1.99B | $2.06B |
| Net income | $992M | $676M | $718M | $1.14B | $1.49B | $1.53B |
| EPS (diluted) | $11.82 | $9.14 | $10.23 | $16.82 | $23.10 | — |
| Free cash flow | $28.0M | $262M | $525M | $1.12B | $849M | $845M |
| Operating margin | 10.8% | 7.5% | 8.2% | 10.6% | 11.5% | 11.4% |
| Net margin | 7.8% | 5.0% | 5.0% | 7.2% | 8.6% | 8.4% |
| Revenue growth | +9.4% | +6.0% | +6.6% | +10.8% | +9.7% | — |
| Cash + short-term investments | $115M | $103M | $119M | $126M | $138M | — |
| Total debt | $4.19B | $4.81B | $4.91B | $4.50B | $4.80B | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 7.3x · P/S 0.6x · EV/EBITDA 5.9x · EV/Sales 0.9x · P/FCF 13.1x · P/B 1.5x · FCF yield 7.62% · Earnings yield 13.76% · Dividend yield (paid, TTM) 0.45% · Buyback yield (TTM) 9.69% · Net debt $4.76B · EV $15.8B
P/E at fiscal year-ends: Dec 2025 9.4x, Dec 2024 10.7x, Dec 2023 14.9x.

## Superinvestors (SEC 13F-HR, Q2 2026)
2 of 80 tracked investors hold UHS. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| First Eagle Investment | First Eagle Investment Management | 1.13% | $677M | Added +3.0% |
| Richard Pzena | Pzena Investment Management | 0.86% | $293M | Added +3.0% |

## Analysts
Consensus Hold (mean 2.80 on a 1–5 scale), 20 analysts; mean target USD 196.12 (low 166, high 290).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-18 | Leerink Partners | Target raised | Outperform | $198 → $205 |
| 2026-08-20 | RBC Capital | Reiterated | Sector Perform | $183 |
| 2026-08-03 | RBC Capital | Target lowered | Sector Perform | $190 → $183 |
| 2026-07-30 | Goldman Sachs | Target lowered | Neutral | $242 → $190 |
| 2026-07-29 | Morgan Stanley | Target lowered | Equal-Weight | $212 → $191 |
| 2026-07-29 | Guggenheim | Target lowered | Buy | $195 → $189 |
| 2026-07-29 | Cantor Fitzgerald | Reiterated | Neutral | $194 |
| 2026-07-29 | Baird | Target lowered | Neutral | $204 → $166 |
| 2026-07-28 | Cantor Fitzgerald | Reiterated | Neutral | $194 |
| 2026-07-28 | Barclays | Target lowered | Equal-Weight | $179 → $168 |
| 2026-07-20 | Guggenheim | Target lowered | Buy | $211 → $195 |
| 2026-07-13 | Wells Fargo | Target raised | Equal-Weight | $165 → $166 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | -9.4% | +42.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -9.5% | +7.3% |
| Volatility (annualized) | 32.6% | 33.4% |
| Max drawdown | -42.0% (Nov 2025→Jun 2026) | -41.9% (Nov 2025→Jun 2026) |

## Peers (Medical Care Facilities)
ENSG (The Ensign Group, Inc.) USD 178.35 +2.88% · FMS (Fresenius Medical Care AG) USD 22.23 +3.11% · DVA (DaVita Inc.) USD 186.1 +5.25% · EHC (Encompass Health Corporation) USD 126.01 +4.60% · PACS (PACS Group, Inc.) USD 47.5 +1.58% · CHE (Chemed Corp) USD 520.15 +1.72%

## More
Full page: https://nexqual.com/UHS · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)


Other companies that name UHS in their own reports (relationship from UHS's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | UNIVERSAL HEALTH REALTY INCOME TRUST (UHT) | 10-K 2026-02-25 | "Our officers are all employees of UHS through its wholly-owned subsidiary, UHS of Delaware, Inc. In addition, five of our hospital facilities are leased to wholly-owned subsidiaries of UHS, one of our…" |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $5.15 | $5.56 | -7.3% | $4.71B | 15 |
| Next quarter (ends 2026-12-31) | $5.73 | $6.17 | -7.2% | $4.76B | 15 |
| Current fiscal year (ends 2026-12-31) | $22.48 | $23.39 | -3.9% | $18.60B | 14 |
| Next fiscal year (ends 2027-12-31) | $23.89 | $25.16 | -5.0% | $19.49B | 15 |